Recurrent loss-of-function mutations reveal costs to OAS1 antiviral activity in primates
Clayton M. Carey, Apurva A. Govande, Juliane M. Cooper, Melissa K. Hartley, Philip J. Kranzusch, Nels C. Elde
The paper identifies recurrent loss-of-function mutations in OAS1 across primates, showing that the cytotoxic effects of OAS1 activation can outweigh its antiviral benefits, leading to reduced catalytic activity.
Cell Host & Microbe · Jan 31, 2019Peer-reviewedGenetics